Mirtazapine attenuates the expression of nicotine-induced locomotor sensitization in rats
Por:
Barbosa-Méndez S., Jurado N., Matus-Ortega M., Martiñon S., Heinze G., Salazar-Juárez A.
Publicada:
5 oct 2017
Categoría:
Pharmacology
Resumen:
Nicotine is the primary psychoactive component of tobacco. Many
addictive nicotinic actions are mediated by an increase in the activity
of the serotonin (5-HT) system. Some studies show that the 5-HT2A,
5-HT2C, and 5-HT3 receptors have a central role in the induction and
expression of nicotine-induced locomotor sensitization. Mirtazapine, an
antagonist of the alpha(2)-adrenergic receptors, the 5-HT2A/C, and the
5-HT3 receptors, has proven effective in reducing behavioral effects
induced by drugs like cocaine and methamphetamines in human and animal.
In this study, we evaluated the effect of mirtazapine on the locomotor
activity and on the expression of nicotine-induced locomotor
sensitization. We used the nicotine locomotor sensitization paradigm to
assess the effects of mirtazapine on nicotine-induced locomotor activity
and locomotor sensitization. Mirtazapine (30 mg/kg, i.p.) was
administered during extinction. Our study found that mirtazapine
attenuated the expression of locomotor sensitization induced by
different nicotine doses, decreased the duration of locomotor effects
and locomotor activity induced by binge administration of nicotine. In
addition, our study revealed that treatment with mirtazapine for 60 days
produced an enhanced attenuation of nicotine-induced locomotor activity
during the expression phase of behavioral sensitization, compared to
that obtained when mirtazapine was administered for 30 days. This
suggests that use of mirtazapine in controlled clinical trials may be a
useful therapy to maintain abstinence for long periods.
Filiaciones:
Barbosa-Méndez S.:
Molecular Neurobiology and Neurochemistry of Addiction, National Institute of Psychiatry, Ramón de la Fuente Muñiz, Mexico
Jurado N.:
Molecular Neurobiology and Neurochemistry of Addiction, National Institute of Psychiatry, Ramón de la Fuente Muñiz, Mexico
Matus-Ortega M.:
Molecular Neurobiology and Neurochemistry of Addiction, National Institute of Psychiatry, Ramón de la Fuente Muñiz, Mexico
Martiñon S.:
Molecular Neurobiology and Neurochemistry of Addiction, National Institute of Psychiatry, Ramón de la Fuente Muñiz, Mexico
Heinze G.:
Department of Psychiatry and Mental Health, School of Medicine, National University of Mexico, Mexico
Salazar-Juárez A.:
Molecular Neurobiology and Neurochemistry of Addiction, National Institute of Psychiatry, Ramón de la Fuente Muñiz, Mexico
|